As advised via PHARMAC Tender Results of 30 April 2019 there is to be a change in the listing and future sole supply of Clopidogrel tablets 75 mg

New listing from 1 December 2019

Clopidogrel Multichem Tab 75 mg 84                                                                     Pharmacode TBA                     Schedule price $4.60

Incumbent brand

Clopid-Arrow Tab 75 mg 84                                                                          Pharmacode 2443201                       Schedule price $5.44

HSS (Hospital Supply Status) & CSS (Community Supply Status) commences 1 May 2020.

Brand switch fee for Community Pharmacy not advised.

As of the date of this notification ProPharma / PWR cannot accept Clopidogrel-Arrow for credit under any circumstances.

From 1 December 2019 community pharmacies dispensing Clopidogrel tablets 75 mg will need to support patients changing to the new brand and manage stock during the transition.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.

Benefit of staying with incumbent while stock remains available are minimal, but every cent counts:-

Clopid-Arrow : – Average dispensing is 84. Therefore 1 x @ $5.44 x 3% = $0.1632 plus  $0.253 (pack fee) giving you $0.4162

Compared to $4.60 x 3% = $0.1380 plus $0.253 (pack fee) giving you $0.3910

You MUST manage your stock to avoid being caught with stock at the time sole supply commences 1 May 2020. Failure to do so may prove very costly.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply 1 May 2020 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

 

About The Author

Close